Clinical trial
A Phase 2, Multicentre, Double-Blind, Placebo-Controlled, Dose Escalating Trial of the Safety, Pharmacokinetics, and Biological Activity of 3 Consecutive Daily Doses of Serp-1 When Added to Conventional Therapy in Patients With Acute Coronary Syndromes (Non ST-Elevation Myocardial Infarction and/or Unstable Angina)
NCT00243308 is registered in ClinicalTrials.gov with Viron Therapeutics Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicentre, Double-Blind, Placebo-Controlled, Dose Escalating Trial of the Safety, Pharmacokinetics, and Biological Activity of 3 Consecutive Daily Doses of Serp-1 When Added to Conventional Therapy in Patients With Acute Coronary Syndromes (Non ST-Elevation Myocardial Infarction and/or Unstable Angina)
- Lead sponsor
- Viron Therapeutics Inc
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- October 31, 2005
- Completion date
- December 31, 2008
- Enrollment
- 72 (estimated)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
coronary atherosclerosis, coronary restenosis, unstable angina